Novartis Q3 income lags estimates as Alcon, dollar hit results
[ZURICH] Novartis reported third-quarter core net income fell, missing analyst forecasts as the cancer portfolio acquired from GlaxoSmithKline and the Swiss company's newer products failed to offset continuing weakness at its eye-care business Alcon.
The stronger dollar also hurt results.
Core net income fell 2 per cent to US$3.06 billion, the world's biggest seller of prescription drugs reported, compared to the average analyst estimate of US$3.128 billion in a Reuters poll. It rose 13 per cent at constant currencies.
Sales fell 6 per cent to US$12.265 billion, compared to the poll average of US$12.62 billion. They rose 6 per cent at constant currencies.
Novartis still expects annual sales to grow at a mid-single-digit percentage rate, with core operating income growing at high single digits, stripping out currency effects, it said on Tuesday.
Reported net income fell 42 per cent to US$1.8 billion, mainly due to a prior-year gain from the sale of Idenix Pharmaceuticals shares to Merck & Co and a provision of around US$400 million for a legal settlement in a US specialty pharmacies case.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action
France's Casino supermarket chain to axe up to 3,200 jobs